Parallel Advisors, LLC Aclaris Therapeutics, Inc. Transaction History

Parallel Advisors, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 20, 2024	BUY	$7.07 - $17.95 $3,535 - $8,975	500 New	500 $4,000
Q1 2023 Apr 25, 2023	SELL	$7.07 - $17.95 $707 - $1,795	-100 Reduced 16.67%	500 $4,000
Q3 2022 Nov 10, 2022	SELL	$13.07 - $18.22 $313 - $437	-24 Reduced 3.85%	600 $9,000
Q2 2022 Aug 01, 2022	BUY	$10.16 - $17.08 $243 - $409	24 Added 4.0%	624 $9,000
Q1 2022 Apr 28, 2022	BUY	$9.74 - $17.92 $4,870 - $8,960	500 Added 500.0%	600 $11,000
Q2 2021 Aug 06, 2021	SELL	$17.08 - $29.6 $18,787 - $32,560	-1,100 Reduced 91.67%	100 $2,000
Q1 2021 Apr 23, 2021	SELL	$5.86 - $27.73 $2,344 - $11,092	-400 Reduced 25.0%	1,200 $30,000
Q4 2020 Feb 02, 2021	SELL	$2.65 - $7.61 $5,962 - $17,122	-2,250 Reduced 58.44%	1,600 $10,000
Q4 2019 Jan 30, 2020	SELL	$1.02 - $1.97 $408 - $788	-400 Reduced 9.41%	3,850 $7,000
Q2 2019 Aug 05, 2019	BUY	$2.13 - $7.06 $2,662 - $8,825	1,250 Added 41.67%	4,250 $9,000
Q1 2019 May 01, 2019	SELL	$5.63 - $7.84 $7,037 - $9,800	-1,250 Reduced 29.41%	3,000 $18,000
Q4 2018 Feb 05, 2019	BUY	$6.3 - $15.4 $8,442 - $20,636	1,340 Added 46.05%	4,250 $31,000
Q3 2018 Nov 01, 2018	BUY	$14.38 - $20.89 $41,845 - $60,789	2,910 New	2,910 $42,000

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $253M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.